Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma

Harwood, Jared L.; Alexander, John H.; Mayerson, Joel L.

doi:10.1016/j.ocl.2015.06.011

Cited by 24 publications

(17 citation statements)

References 175 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7–9,12,18,19 Bone sarcomas, for example, are often included with STS, but may be managed with a different algorithm, given their chemotherapy responsiveness. 20 The purpose of this investigation was to identify factors associated with longer OS and disease-free recurrence after the first resection, using a large single-institution database of patients undergoing PM for STS. The identification of these factors will help thoracic surgeons determine which subset(s) of patients are most likely to benefit from PM.…”

Section: Introductionmentioning

confidence: 99%

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma

Chudgar

Brennan

Munhoz

et al. 2017

The Journal of Thoracic and Cardiovascular Surgery

100

View full text Add to dashboard Cite

OBJECTIVE Soft tissue sarcoma is a heterogeneous disease that frequently includes the development of pulmonary metastases. The purpose of this study is to determine factors associated with improved survival among patients with soft tissue sarcoma to help guide selection for pulmonary metastasectomy. METHODS We reviewed a prospectively maintained database and identified 803 patients who underwent pulmonary metastasectomy for metastatic soft tissue sarcoma between September 1991 and June 2014; of these, 539 patients undergoing 760 therapeutic-intent pulmonary metastasectomies were included. Clinicopathologic variables and characteristics of treatment were examined. The outcomes of interest were overall survival and disease-free survival. Survival was estimated using the Kaplan-Meier method and compared between variables using the log-rank test. Factors associated with hazard of death and recurrence were identified using univariable and multivariable Cox proportional hazards models. RESULTS Median overall survival was 33.2 months (95% confidence interval, 29.9–37.1), and median disease-free survival was 6.8 months (95% confidence interval, 6.0–8.0). In multivariable analyses, leiomyosarcoma histologic subtype (p=0.007), primary tumor size ≤10 cm (p=0.006), increasing time from primary tumor resection to development of metastases (p<0.001), solitary lung metastasis (p=0.001), and minimally invasive resection (p=0.023) were associated with lower hazard of death. Disease-free interval ≥1 year (p=0.002), and 1 pulmonary metastasis (p<0.001) were associated with lower hazard of disease recurrence. CONCLUSIONS In a large single-institution study, primary tumor histologic subtype and size, numbers of pulmonary metastases, disease-free interval, and selection for minimally invasive resection are associated with increased survival in patients undergoing pulmonary metastasectomy for soft tissue sarcoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma

Chudgar

Brennan

Munhoz

et al. 2017

The Journal of Thoracic and Cardiovascular Surgery

100

View full text Add to dashboard Cite

show abstract

“…A central issue in achieving successful less-ablative resections is the ability to safely utilize closer surgical margins than those traditionally used. Targeted chemotherapy agents such as tyrosine kinase inhibitors and m-TOR inhibitors may also allow for increasingly smaller margins than what has previously been recommended [1].…”

Section: Where Do We Need To Go?mentioning

confidence: 99%

CORR Insights®: Is It Possible and Safe to Perform Acetabular-preserving Resections for Malignant Neoplasms of the Periacetabular Region?

Mayerson

2017

Clinical Orthopaedics &Amp; Related Research

Self Cite

View full text Add to dashboard Cite

“…CRISPR-Cas9 is capable of inducing loss of function (LOF), and gain of function (GOF) mutations in vitro and in vivo . So far, CRISPR-Cas9 has been used in some malignant tumor models, including lung cancer, colorectal cancer, and myeloid leukemia [22, 27, 28, 30, 31]. By delivering the combination of sgRNA and Cas9 with a lentiviral vector, five genes ( TET2 , DNMT3A , RUNX1 , NF1 , and EZH2 ) demonstrated LOF in a single hematopoietic stem cell, leading to clonal outgrowth and myeloid malignancy [30].…”

Section: Potential Applications Of Crispr-cas9 In Sarcomamentioning

confidence: 99%

“…Sarcoma is a rare and heterogeneous group of tumors with 50 different subtypes that exhibit a wide range of differing behaviors and underlying molecular mechanisms [6, 28]. Sarcoma is believed to arise in mesenchymal tissues and often displays highly aggressive behavior with proclivity towards early hematogenous metastasis [15, 62].…”

Section: Introductionmentioning

confidence: 99%

Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma

Liu

Shen

et al. 2016

Cancer Letters

View full text Add to dashboard Cite

Sarcomas include some of the most aggressive tumors and typically respond poorly to chemotherapy. In recent years, specific gene fusion/mutations and gene over-expression/activation have been shown to drive sarcoma pathogenesis and development. These emerging genomic alterations may provide targets for novel therapeutic strategies and have the potential to transform sarcoma patient care. The RNA-guided nuclease CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein-9 nuclease) is a convenient and versatile platform for site-specific genome editing and epigenome targeted modulation. Given that sarcoma is believed to develop as a result of genetic alterations in mesenchymal progenitor/stem cells, CRISPR-Cas9 genome editing technologies hold extensive application potentials in sarcoma models and therapies. We review the development and mechanisms of the CRISPR-Cas9 system in genome editing and introduce its application in sarcoma research and potential therapy in clinic. Additionally, we propose future directions and discuss the challenges faced with these applications, providing concise and enlightening information for readers interested in this area.

show abstract

Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma

Cited by 24 publications

References 175 publications

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma

Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma

CORR Insights®: Is It Possible and Safe to Perform Acetabular-preserving Resections for Malignant Neoplasms of the Periacetabular Region?

Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma

Contact Info

Product

Resources

About